Dec. 2, 2024

UCalgary researchers help preserve future fertility options for children impacted by cancer

Next to survival, fertility is the No. 1 concern for young patients and their parents
Adult with arm around child
Michelle carried the same rare genetic mutation that led to a fatal cancer diagnosis for her mom. Kelly Johnston, Cumming School of Medicine

University of Calgary researchers are giving children and adolescents whose fertility may be impacted by cancer, or treatments associated with cancer, new hope of having their own biological child, one day. Advancements in technology and scientific understanding are creating new possibilities to preserve fertility.

“We have established an ovarian tissue cryopreservation (OTC) program in Calgary,” says Dr. Shu Foong, MD’97, specialist in reproductive endocrinology and infertility and clinical assistant professor at the Cumming School of Medicine (CSM). “For the first time, prepubertal patients with ovaries who are facing cancer treatments that may impact their fertility have an option that they may be able to have their own biological child one day.”

Ryan understands the devastating consequences of cancer treatment on fertility. As a boy, he was diagnosed with acute lymphoblastic leukemia. He underwent two years of chemotherapy. After being cancer-free for a time, the cancer returned and was localized to his testicles. He was too young to preserve sperm. 

The radiation treatments were effective in stopping the cancer and saving Ryan’s life, however the treatment left him infertile. When he married, and began family planning, Ryan and his wife investigated what options were available to them. In the end, Ryan’s wife was able to conceive through invitro fertilization with donor sperm. Now, many years later Ryan was offered the chance to preserve fertility for his daughter.

“Michelle was only nine years old when we learned she had the same rare gene mutation that led to a fatal cancer diagnosis for her mother,” says Ryan. “We knew the only way to prevent this aggressive cancer was preventive surgery. I could save Michelle’s life, and thanks to Dr. Foong, I could also offer Michelle an opportunity to make her own decision about having her own children when she’s ready.”

Shu Foong

Shu Foong says many people are amazed at how fast science and technology has opened the doors for fertility care in children or adolescents facing cancer.

Riley Brandt, University of Calgary

Families first meet with an oncologist, who introduces the fertility preservation option as part of the care plan where a child or adolescent is facing aggressive chemotherapy and/or radiation therapy that is likely to impact their fertility. A person born with ovaries has all the eggs for their lifetime at birth. However, for patients who undergo high doses of chemotherapy or radiation therapy, it can sometimes cause them to go into premature menopause.

OTC involves removing a portion or the whole ovary through laparoscopy using a camera and small incisions before cancer treatment starts. The tissue is cryopreserved using a technique called slow-freezing or vitrification so that it may be reimplanted at a future date. Foong and colleagues, Drs. Sarah McQuillan, MD, and Gregory Guilcher, MD, say they’ve had an overwhelmingly positive response from families about the program.

Drs. Greg Guilcher and Sarah McQuillan

Drs. Greg Guilcher and Sarah McQuillan

Riley Brandt

“OTC is the only option for fertility preservation for a young girl who is prepubertal and sometimes also the only option for girls who are post puberty, depending on the specific situation,” says Guilcher, a pediatric hematologist/oncologist and associate professor at CSM. “Having this expertise and leadership in Calgary is a wonderful option for our young patients and their families.”

Preserving hope and building expertise to help more families

Cryopreservation of ovarian tissue is a relatively new technique, however in many places in the world it is no longer considered experimental and is now part of routine care that has resulted in hundreds of births worldwide.

Calgary is one of the few centres in Canada that routinely offers OTC as part of the standard of care embedded in the treatment process when starting high-risk treatment. The program started in 2015 after Foong returned from an international conference. 

“I was attending a congress on oncofertility when I realized it was time for such a program to exist, not just here in Calgary, but also for Canadians,” says Foong. “We started out just as a team of two. It was just Kim Parker, master of science in clinical embryology, and me. I am thrilled to say we have gone from a team of two to a multidisciplinary team involving social workers, nurses, physicians and scientists who are all collaborating for the betterment of our patient care.”

McQuillan is the program director for the Pediatric and Adolescent Gynecology Fellowship, one of three in the country.  

This is our sixth year with the fellowship and we have been very lucky to train fellows that have both stayed in Calgary as well as established their practice all over the world and Canada,” says McQuillan, clinical associate professor at the CSM.

“In terms of cancer, survival in the pediatric population in Canada is approaching 90 per cent, now. Reproductive potential in the future is so important because it gives them hope for a future 10, 20, 30 years down the road and that they will be able to build their own family with their own biological children if they would desire that in the future,” says McQuillan.

The clinicians say the field of oncofertility is advancing quickly. Foong envisions expanding the program to include fertility preservation for pre-pubescent children with testes as well as ovaries. 

“Many people are amazed at how fast science and technology have opened the doors for fertility care in children or adolescents facing cancer. What was once just a dream is now a reality and we sure hope to push that further. Other centres in the world are starting to show success with testicular tissue freezing,” says Foong. “The technology is rapidly evolving. We want to continue to build our program to meet the needs of all our patients.” 

Next to survival, fertility is the No. 1 concern 

Dr. Miranda Fidler-Benaoudia, PhD, is a cancer epidemiologist who researches the long-term psychological and lifestyle effects of surviving cancer at a young age. 

“Of course, when you’re an adolescent, say 14 years old, and facing cancer you may not be thinking about whether or not you want to have children in the future. But, what research has shown is that later in life, just knowing infertility is a possibility causes a lot of emotional distress for survivors of childhood and adolescent cancer. Some young survivors have even expressed that an infertility diagnosis is as distressing as cancer,” says Fidler-Benaoudia, an adjunct associate professor at the CSM. “All initiatives to make oncofertility available to young cancer survivors should be applauded, and efforts should continue to make sure these services are equitably accessible too.” 

Guilcher says OTC is changing the conversations he’s having with many of his patients and their families.

“When we meet with families facing a cancer diagnosis, a discussion about fertility is not only hugely important to them because most people want to have that option available to them in the future, but also it's immediately conveying hope at a very difficult time in their lives that there is a long-term future to look forward to and that we are also thinking about a long-term future for their child.”

Up to this point, the program has been fueled by the team’s passion to create more options for young patients and not just those with cancer. 

Also importantly, we do bone marrow transplants not only for children with cancer, but children and young people with non-malignant conditions, like serious blood disorders such as sickle cell disease or thalassemia. These young patients require chemotherapy or radiation as part of the bone marrow transplant procedure, which can compromise fertility.”

Currently OTC is not covered by Alberta Health. The researchers along with the families they’ve helped are hoping to see that change to ensure there are no barriers to OTC for any child.

“I hope that in my career I will soon see the day where cost is not a barrier for all our patients to access care,” says Foong. “Costs should not be an obstacle for a young child to gain access to the OTC program. Any child or their families should be able to access OTC as a piece of hope that they will store away for the future.”

The team anticipates 40 families per year would be interested in access to OTC.

The names of the family members referenced in this article have been changed out of respect for their privacy. 

Shu Foong is a clinical assistant professor in the Department of Obstetrics and Gynaecology at the Cumming School of Medicine. She is the medical director of the Regional Fertility Program.

Greg Guilcher is an associate professor at departments of Oncology and Paediatrics at the Cumming School of Medicine (CSM). He is a member of the Alberta Children’s Hospital Research Institute and the Arnie Charbonneau Cancer Institute at the CSM. 

Sarah McQuillan is a clinical associate professor in the Department of Obstetrics and Gynaecology and program director for the Pediatric and Adolescent Gynecology Fellowship at the Cumming School of Medicine (CSM). She is a member of the Alberta Children’s Hospital Research Institute at the CSM. 

Miranda Fidler-Benaoudia is an adjunct associate professor in the departments of Oncology and Community Health Sciences at the Cumming School of Medicine (CSM). She is a member of the Alberta Children’s Hospital Research Institute, the Arnie Charbonneau Cancer Institute and the O’Brien Institute of Public Health at the CSM.